Table 3. Comparison of clinical characteristics between groups stratified by changes in lung tumor at resection.
| Parameters | Non-progressive disease group | Tumor progression group | P value |
|---|---|---|---|
| Number | 19 | 21 | |
| Clinical stage at diagnosis, n (%) | 0.01 | ||
| Stage I–II | 1 (5.3) | 2 (9.5) | |
| Stage III | 10 (52.6) | 2 (9.5) | |
| Stage IV | 8 (42.1) | 17 (81.0) | |
| Duration of prior TKI treatment (months), median (range) | 10.5 (2.6–67.8) | 20.1 (3.5–68.6) | 0.044 |
| Clinical stage at initiation of TKI, n (%) | 0.02 | ||
| Stage III | 7 (36.8) | 2 (9.6) | |
| Stage IV | 12 (63.2) | 19 (90.5) | |
| Clinical stage at resection, n (%) | 0.07 | ||
| Stage II | 1 (5.3) | 0 (0.0) | |
| Stage III | 7 (36.8) | 2 (10.0) | |
| Stage IV | 11 (57.9) | 18 (90.0) | |
| Change of cancer stage between TKI initiation and later resection (TNM), n (%) | 0.08 | ||
| Downstaged | 3 (15.8) | 0 (0.0) | |
| Unchanged | 16 (84.2) | 18 (90.0) | |
| Upstaged | 0 (0.0) | 2 (10.0) | |
| Tumor differentiation level from resected sample (n=37), n (%) | n=18 | n=19 | 0.49 |
| Well | 0 (0.0) | 1 (5.3) | |
| Moderate | 11 (61.1) | 9 (47.4) | |
| Poor | 7 (38.9) | 9 (47.4) | |
| Lymphovascular invasion† (n=37), n (%) | n=18 | n=19 | 0.94 |
| None | 5 (27.8) | 6 (30.0) | |
| Lymphatic | 5 (27.8) | 4 (20.0) | |
| Vascular | 2 (11.1) | 2 (10.0) | |
| Both | 6 (33.3) | 8 (40.0) | |
| T790M mutation at resection (n=36), n/total (%) | 4/16 (25.0) | 7/20 (35.0) | 0.58 |
| PD-L1 SP263, diagnosis (n=27) , n (%) | n=14 | n=13 | 0.55 |
| 0% | 7 (50.0) | 5 (38.5) | |
| ≥1% | 7 (50.0) | 8 (61.5) | |
| PD-L1 22C3 at diagnosis (n=24), n (%) | n=14 | n=10 | 0.24 |
| 0% | 5 (35.7) | 6 (60.0) | |
| ≥1% | 9 (64.3) | 4 (40.0) | |
| PD-L1 SP263, resected sample (n=27), n (%) | n=14 | n=13 | <0.001 |
| 0% | 11 (78.6) | 1 (7.7) | |
| ≥1% | 3 (21.4) | 12 (92.3) | |
| PD-L1 22C3, resected sample (n=24), n (%) | n=13 | n=11 | 0.09 |
| 0% | 8 (61.5) | 3 (27.3) | |
| ≥1% | 5 (38.5) | 8 (72.7) | |
| Viable tumor cell from resected sample (n=25), n (%) | 0.16 | ||
| ≤10% | 2 (15.4) | 0 (0.0) | |
| >10% | 11 (84.6) | 12 (100.0) | |
| PFS and postoperative survival, n/total (%) | |||
| 6-month PFS rate (n=40) | 16/19 (84.2) | 12/21 (57.1) | 0.06 |
| 1-year PFS rate (n=39) | 13/19 (68.4) | 10/20 (50.0) | 0.24 |
| 18-month PFS rate (n=30) | 5/11 (45.5) | 8/19 (42.1) | 0.86 |
| 1-year postoperative survival rate | 18/18 (100.0) | 15/17 (88.2) | 0.13 |
| 2-year postoperative survival rate | 4/5 (80.0) | 10/14 (71.4) | 0.71 |
†, this parameter is assessed only in patients with regarding data. TKI, tyrosine kinase inhibitor; TNM, tumor, node, metastasis; PD-L1, programmed death-ligand 1; PFS, progression-free survival.